Keyword: Intellia Therapeutics
Intellia clinical head to be Casebia’s first CMO; Ferring CSO to take over for retiring board president; and Harpoon names new CFO and CSO.
Intellia Therapeutics’ clinical development head, Adel Nada, left to serve as the first chief medical officer of Casebia Therapeutics.
Intellia Therapeutics is developing a CRISPR-based treatment to edit the mutation that causes transthyretin amyloidosis.
In a blow to the University of California, a federal appeals court upheld CRISPR patents held by the Broad Institute.
Editas Medicine is to lose its chief medical officer at the end of the year, as the search is on for a new clinical leader.
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.
Another study warns of potential toxicity with CRISPR gene-editing, and gives investors in biotechs developing the technology the jitters.
Inscripta offers its CRISPR enzymes for free, but the biotech plans to make its money selling CRISPR tools.
A couple of months ago, Intellia’s leader and founder Nessan Bermingham, Ph.D., left the CRISPR company, but we knew not where.
A new journal paper has found that the CRISPR-Cas9 gene-editing technique could be under threat from the body’s own immune system.